Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR442085 in Relapsed or Refractory Multiple Myeloma
NCT04000282Phase 1Completed
- Sponsor
- Sanofi
- Start
- Aug 2019
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 6
01
Overview
Phase 1, open-label trial of sar442085 in multiple myeloma (MM) (2 arms), sponsored by Sanofi. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 1 more. Started Aug 2019; status: completed.
02
Drugs
sar442085
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04000282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04000282.